MCID: ANP009
MIFTS: 41

Anaplastic Oligodendroglioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Anaplastic Oligodendroglioma

MalaCards integrated aliases for Anaplastic Oligodendroglioma:

Name: Anaplastic Oligodendroglioma 12 20 58 54 17 70
Oligodendroglioma, Anaplastic 6

Characteristics:

Orphanet epidemiological data:

58
anaplastic oligodendroglioma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:7154
NCIt 50 C4326
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 71 C0334590
Orphanet 58 ORPHA251630
UMLS 70 C0334590

Summaries for Anaplastic Oligodendroglioma

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 251630 Definition A rare glial tumor characterized by a grade III oligodendroglial tumour with focal or diffuse anaplastic features. It typically occurs in the supratentorial white matter. Histologically, the cells are enlarged and epithelioid with pleomorphic and increased size nuclei, a vesicular chromatin pattern and prominent nucleoli. Most patients present with seizures.

MalaCards based summary : Anaplastic Oligodendroglioma, also known as oligodendroglioma, anaplastic, is related to oligoastrocytoma and malignant astrocytoma, and has symptoms including seizures and headache. An important gene associated with Anaplastic Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), and among its related pathways/superpathways are Neural Crest Differentiation and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Vincristine and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotypes are neoplasm and respiratory system

Disease Ontology : 12 An oligodendroglioma that is characterized by focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).

Wikipedia : 73 Anaplastic oligodendroglioma is a neuroepithelial tumor which is believed to originate from... more...

Related Diseases for Anaplastic Oligodendroglioma

Diseases related to Anaplastic Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 30.9 MGMT IDH2
2 malignant astrocytoma 30.1 OLIG2 MGMT IDH2
3 brain glioma 29.9 MGMT IDH2
4 low grade glioma 29.8 MGMT IDH2
5 mixed glioma 29.5 OLIG2 MGMT IDH2
6 brain cancer 29.4 OLIG2 OLIG1 MGMT IDH2
7 oligodendroglioma 29.4 POT1 OLIG2 OLIG1 MGMT IDH2 CIC
8 pilocytic astrocytoma 29.3 OLIG2 MGMT
9 anaplastic astrocytoma 29.1 OLIG2 OLIG1 MGMT IDH2
10 anaplastic oligodendroglioma, idh-mutant and 1p/19q-codeleted 11.5
11 glioblastoma 10.4
12 anaplastic oligoastrocytoma 10.4
13 high grade glioma 10.4
14 glioma susceptibility 1 10.4
15 glial tumor 10.3
16 glioma 10.3
17 arteriovenous malformation 10.2
18 parkinson disease, late-onset 10.1
19 hydrocephalus 10.1
20 central neurocytoma 10.1
21 gangliocytoma 10.1
22 ganglioglioma 10.1
23 adult oligodendroglioma 10.0 OLIG2 IDH2
24 adult brain stem glioma 10.0 MGMT IDH2
25 mixed oligodendroglioma-astrocytoma 10.0 MGMT IDH2
26 cerebral cavernous malformations 9.9
27 retinoblastoma 9.9
28 williams-beuren syndrome 9.9
29 lymphoma, hodgkin, classic 9.9
30 lymphoma, non-hodgkin, familial 9.9
31 meningioma, familial 9.9
32 psoriatic arthritis 9.9
33 leukemia, acute lymphoblastic 9.9
34 childhood acute lymphocytic leukemia 9.9
35 lymphoblastic lymphoma 9.9
36 hepatic veno-occlusive disease 9.9
37 intracranial meningioma 9.9
38 disseminated intravascular coagulation 9.9
39 pneumocystosis 9.9
40 neutropenia 9.9
41 pancytopenia 9.9
42 acute leukemia 9.9
43 thrombocytopenia 9.9
44 status epilepticus 9.9
45 relapsing-remitting multiple sclerosis 9.9
46 agammaglobulinemia 9.9
47 spinal cord oligodendroglioma 9.9
48 lynch syndrome 9.9
49 secretory meningioma 9.9
50 lymphoplasmacyte-rich meningioma 9.9

Graphical network of the top 20 diseases related to Anaplastic Oligodendroglioma:



Diseases related to Anaplastic Oligodendroglioma

Symptoms & Phenotypes for Anaplastic Oligodendroglioma

UMLS symptoms related to Anaplastic Oligodendroglioma:


seizures; headache

MGI Mouse Phenotypes related to Anaplastic Oligodendroglioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.26 CDKN2C IDH2 MGMT OLIG2
2 respiratory system MP:0005388 8.92 CDKN2C CIC MGMT OLIG2

Drugs & Therapeutics for Anaplastic Oligodendroglioma

Drugs for Anaplastic Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
2
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
3
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
4 Alkylating Agents Phase 3
5 Tubulin Modulators Phase 3
6 Antimitotic Agents Phase 3
7
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
8
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
9
Lenograstim Approved, Investigational Phase 2 135968-09-1
10
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
11
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
12
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
13
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 6251 453
14
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
15
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
16
Busulfan Approved, Investigational Phase 2 55-98-1 2478
17
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
18
Trioxsalen Approved Phase 2 3902-71-4 5585
19
Phenylalanine Approved, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2 6140
20 Antimetabolites Phase 2
21 Protein Kinase Inhibitors Phase 1, Phase 2
22 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
23 topoisomerase I inhibitors Phase 2
24 Anti-Infective Agents Phase 1, Phase 2
25 Antidotes Phase 1, Phase 2
26 Etoposide phosphate Phase 1, Phase 2
27 sodium thiosulfate Phase 1, Phase 2
28 diuretics Phase 1, Phase 2
29 Chelating Agents Phase 1, Phase 2
30 Keratolytic Agents Phase 1, Phase 2
31 Antioxidants Phase 1, Phase 2
32 Anti-Bacterial Agents Phase 1, Phase 2
33 Antitubercular Agents Phase 1, Phase 2
34 Nitrogen Mustard Compounds Phase 1, Phase 2
35 Podophyllotoxin Phase 1, Phase 2 518-28-5
36 Protective Agents Phase 1, Phase 2
37 Immunosuppressive Agents Phase 2
38 Immunologic Factors Phase 2
39 O(6)-benzylguanine Phase 2
40 Pharmaceutical Solutions Phase 2
41 Dihematoporphyrin Ether Phase 2
42 Ether Phase 2
43 Photosensitizing Agents Phase 2
44 Hematoporphyrin Derivative Phase 2
45 Dermatologic Agents Phase 2
46
L-Alanine Nutraceutical Phase 1, Phase 2 56-41-7 5950
47
Sorafenib Approved, Investigational Phase 1 284461-73-0 216239 406563
48
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
49
Flucytosine Approved, Investigational Phase 1 2022-85-7 3366
50
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
2 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
4 Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria Completed NCT00717197 Phase 2 Capecitabine
5 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
6 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
7 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
8 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
9 Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal Completed NCT00003465 Phase 2 temozolomide
10 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
11 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
12 A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
13 Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma or Oligoastrocytoma Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
14 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Active, not recruiting NCT00588523 Phase 2 temozolomide followed by high dose busulfan and thiotepa
15 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
16 A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults Terminated NCT01966809 Phase 2 Photofrin photodynamic therapy.
17 A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants Completed NCT00979173 Phase 1 AC480
18 A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma Completed NCT01156584 Phase 1 Toca FC
19 A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas Completed NCT01144247 Phase 1 alloreactive CTL
20 A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC Completed NCT01985256 Phase 1 Toca FC
21 Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation
22 A Phase I Dose-finding and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent or Refractory Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Mixed Oligo-astrocytoma (AOA), Glioblastoma Multiforme (GBM) or Gliosarcoma (GS), With or Without Concurrent Treatment With Enzyme-inducing Anticonvulsant Therapy Completed NCT00526812 Phase 1 RTA 744;RTA 744 injection
23 A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 Terminated NCT04327011 Phase 1 Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
24 Phase I Pharmacodynamic and "High Content" Study of the Gamma-Secretase Inhibitor RO4929097 in Patients With Recurrent Malignant Gliomas (MGs) Targeting p75NTR to Inhibit Brain Tumor Initiating Cells (BTICs) and Recurrent Invasive Gliomas Terminated NCT01269411 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097
25 Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma Withdrawn NCT00734864 Phase 1 enzyme-inducing anti-epileptic drugs;enzyme-inducing anti-epileptic drugs
26 Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma; Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis. No longer available NCT02755987 ANG1005
27 Pilot Trial of NovoTTF -200A (TTFields) in Patients With Newly Diagnosed High Risk Oligodendrogliomas Withdrawn NCT03353896

Search NIH Clinical Center for Anaplastic Oligodendroglioma

Genetic Tests for Anaplastic Oligodendroglioma

Anatomical Context for Anaplastic Oligodendroglioma

MalaCards organs/tissues related to Anaplastic Oligodendroglioma:

40
Brain, Eye, Spinal Cord, Bone Marrow, Bone, Breast, Myeloid

Publications for Anaplastic Oligodendroglioma

Articles related to Anaplastic Oligodendroglioma:

(show top 50) (show all 597)
# Title Authors PMID Year
1
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. 54 61
19805356 2009
2
[Temozolomide: Temodal]. 61 54
18347414 2008
3
Serum GFAP is a diagnostic marker for glioblastoma multiforme. 61 54
17998256 2007
4
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. 54 61
17440165 2007
5
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. 61 54
17319279 2007
6
[Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. 61 54
17236582 2006
7
Malignant glioma: neuropathology and neurobiology. 61 54
16944363 2006
8
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. 54 61
15455350 2005
9
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. 61 54
11438483 2001
10
Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. 54 61
11307615 2001
11
Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. 54 61
10515227 1999
12
Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. 54 61
10485462 1999
13
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. 61 54
9776413 1998
14
Epidermal growth factor receptor expression in oligodendroglial tumors. 54 61
8686753 1996
15
Lectins: reliable differentiation markers in human oligodendrogliomas. 61 54
8220777 1993
16
IDH-mutant gliomas with additional class-defining molecular events. 61
33772213 2021
17
TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. 61
33783067 2021
18
Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report. 61
33395066 2021
19
Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma. 61
33001573 2021
20
Anaplastic Oligodendroglioma - Is Adjuvant Radiotherapy Mandatory following Maximal Surgical Resection?: Grade 3 Oligo Radiotherapy. 61
33109468 2021
21
High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis. 61
32761642 2020
22
Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future. 61
33260137 2020
23
Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases. 61
33214617 2020
24
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO). 61
33025213 2020
25
Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas. 61
32324987 2020
26
Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. 61
33009979 2020
27
Simultaneous Bilateral Femoral Neck Fracture Due to a Tonic-Clonic Seizure and High-Dose Steroid Therapy. 61
32695869 2020
28
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. 61
32823925 2020
29
Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas. 61
32859823 2020
30
5-ALA False-Positive in Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-codeleted. 61
32243563 2020
31
Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network. 61
31561286 2020
32
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. 61
32293798 2020
33
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. 61
32169363 2020
34
Involvement of the Olfactory Apparatus by Gliomas. 61
32165363 2020
35
A novel PTPRZ1-ETV1 fusion in gliomas. 61
31381204 2020
36
Spinal leptomeningeal oligodendrogliomatosis after resection of cerebral anaplastic oligodendoglioma with 1p19q Co-deletion - A case report. 61
32007374 2020
37
Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and IDH2-mutant anaplastic oligodendroglioma: a case report and literature review. 61
33005899 2020
38
Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. 61
33520712 2020
39
Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. 61
33373402 2020
40
Role of the default mode resting-state network for cognitive functioning in malignant glioma patients following multimodal treatment. 61
32540630 2020
41
CyTOF Analysis Reveals a Distinct Immunosuppressive Microenvironment in IDH Mutant Anaplastic Gliomas. 61
33614475 2020
42
Histological features in pediatric central nervous system tumors with FGFR alterations. 61
33480239 2020
43
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. 61
31028406 2020
44
5-Aminolevulinic Acid Multispectral Imaging for the Fluorescence-Guided Resection of Brain Tumors: A Prospective Observational Study. 61
32733798 2020
45
[Spinal cord metastasis of anaplastic oligodendroglioma of the brain without recurrence of primary tumor. Ccase report and literature review]. 61
32759927 2020
46
Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma. 61
30977078 2019
47
High-grade Glioma Masquerading as a Small Cerebral Hemorrhage: A Case Report. 61
31849570 2019
48
Experience Profiling of Fluorescence-Guided Surgery I: Gliomas. 61
31686440 2019
49
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01. 61
31686436 2019
50
Anaplastic Oligodendroglioma with Transdural Extension. 61
31254692 2019

Variations for Anaplastic Oligodendroglioma

ClinVar genetic disease variations for Anaplastic Oligodendroglioma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CIC NM_015125.4(CIC):c.643C>T (p.Arg215Trp) SNV Likely pathogenic 635170 rs1568504941 GRCh37: 19:42791757-42791757
GRCh38: 19:42287605-42287605

Expression for Anaplastic Oligodendroglioma

Search GEO for disease gene expression data for Anaplastic Oligodendroglioma.

Pathways for Anaplastic Oligodendroglioma

Pathways related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.96 OLIG2 OLIG1
2 10.52 OLIG2 OLIG1

GO Terms for Anaplastic Oligodendroglioma

Biological processes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron fate commitment GO:0048663 8.96 OLIG2 OLIG1
2 oligodendrocyte differentiation GO:0048709 8.8 OLIG2 OLIG1 CDKN2C

Molecular functions related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.02 POT1 OLIG2 OLIG1 MGMT CIC

Sources for Anaplastic Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....